Tallimustine

Summary

Tallimustine (FCE 24517) is an experimental antineoplastic peptide-polyamide conjugate derived from distamycin A coupled to a benzoyl nitrogen mustard moiety. It demonstrates potent cytotoxic activity with sequence-selective DNA minor groove alkylation. Phase I and II clinical trials were conducted in the 1990s–2000s for various solid tumors and hematologic malignancies, but development was halted primarily due to dose-limiting myelosuppression. It remains a research/investigational compound and is not approved for clinical use.

Mechanism of Action

Tallimustine is a benzoyl nitrogen mustard derivative of the natural antibiotic distamycin A. It binds to the minor groove of DNA with sequence selectivity (preferring AT-rich sequences, particularly at the N3 of adenine in runs of four or more AT base pairs) and alkylates DNA, leading to DNA strand breaks, inhibition of replication, and apoptosis in rapidly dividing cells.

Routes of Administration

Goals & Uses

• Solid tumor treatmentOncologyLow
• Sequence-selective DNA alkylation researchResearchModerate
• Hematologic malignancy treatmentOncologyLow

Contraindications

• Severe hepatic impairmentOrganModerateLiver function concerns
• Pre-existing severe bone marrow suppressionHematologicHigh
• Severe renal impairmentOrganModerateKidney function concerns
• PregnancyPopulationHighPotential fetal risk or insufficient safety data

Adverse Effects

• HepatotoxicityHepaticUncommonLiver injury or dysfunction
• AlopeciaDermatologicUncommonHair loss
• Nausea and vomitingGastrointestinalCommon
• MucositisGastrointestinal / MucosalUncommon
• Myelosuppression (neutropenia, thrombocytopenia)HematologicCommon
• Fatigue/astheniaGeneralCommon

Drug Interactions

• Live attenuated vaccinesHigh
• Other myelosuppressive agentsHigh

Population Constraints

• Pediatric patientsAgeRelative
• Pregnant or breastfeeding womenReproductiveAbsolute
• Elderly patientsAgeRelative

Regulatory Status

• European UnionInvestigationalClinical trials conducted in European centers; no marketing authorization ever granted.
• United StatesInvestigationalStudied under IND in Phase I/II trials; never approved by FDA.
• United KingdomInvestigationalNo approval; remained investigational only.

Never received regulatory approval in any jurisdiction. Investigated under clinical trial frameworks in Europe and the United States. Development was discontinued; no approved indications exist.

Evidence & Sources

No sources recorded yet.